AU1067795A - Use of lithium compounds in the treatment and prevention of alzheimer's disease - Google Patents
Use of lithium compounds in the treatment and prevention of alzheimer's diseaseInfo
- Publication number
- AU1067795A AU1067795A AU10677/95A AU1067795A AU1067795A AU 1067795 A AU1067795 A AU 1067795A AU 10677/95 A AU10677/95 A AU 10677/95A AU 1067795 A AU1067795 A AU 1067795A AU 1067795 A AU1067795 A AU 1067795A
- Authority
- AU
- Australia
- Prior art keywords
- alzheimer
- disease
- prevention
- treatment
- lithium compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to the use of lithium compounds in the treatment and prevention of Alzheimer's disease. It also concerns a pharmaceutical agent containing at least one lithium compound and at least one acetylcholinesterase inhibitor in a fixed combination for use in the treatment and prevention of Alzheimer's disease.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19934340272 DE4340272C1 (en) | 1993-11-26 | 1993-11-26 | Pharmaceutical composition for the optimised treatment of Alzheimer's disease and for preventing progression of this disease |
DE19934340273 DE4340273A1 (en) | 1993-11-26 | 1993-11-26 | Medicament contg. lithium cpd. |
DE4340273 | 1993-11-26 | ||
DE4340272 | 1993-11-26 | ||
PCT/EP1994/003921 WO1995014481A1 (en) | 1993-11-26 | 1994-11-26 | Use of lithium compounds in the treatment and prevention of alzheimer's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
AU1067795A true AU1067795A (en) | 1995-06-13 |
Family
ID=25931542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU10677/95A Abandoned AU1067795A (en) | 1993-11-26 | 1994-11-26 | Use of lithium compounds in the treatment and prevention of alzheimer's disease |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0730463B1 (en) |
AT (1) | ATE189391T1 (en) |
AU (1) | AU1067795A (en) |
DE (1) | DE59409129D1 (en) |
WO (1) | WO1995014481A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI1000970A2 (en) * | 2010-04-07 | 2011-11-29 | Fundacao Arnaldo Vieira De Carvalho | pharmaceutical composition for the treatment of Alzheimer's disease, process for its obtaining and use |
MX2018015464A (en) * | 2016-06-13 | 2019-05-27 | Syneurx Int Taiwan Corp | Use of lithium benzoate for treating central nervous system disorders. |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8601915D0 (en) * | 1986-01-27 | 1986-03-05 | Efamol Ltd | Pharmaceutical compositions |
EP0289204B1 (en) * | 1987-04-27 | 1991-07-17 | Efamol Holdings Plc | Lithium salt-containing pharmaceutical compositions |
HU207444B (en) * | 1990-07-12 | 1993-04-28 | Biorex Kutato Fejlesztoe Kft | Method for producing therapeutical preparation suitable for treating alzheimer-disease |
US5155226A (en) * | 1991-02-19 | 1992-10-13 | Hoechst-Roussel Pharmaceuticals Incorporated | Method for the preparation of 9-amino-1,2,3,4-tetrahydroacridine |
-
1994
- 1994-11-26 AT AT95901442T patent/ATE189391T1/en not_active IP Right Cessation
- 1994-11-26 AU AU10677/95A patent/AU1067795A/en not_active Abandoned
- 1994-11-26 DE DE59409129T patent/DE59409129D1/en not_active Expired - Fee Related
- 1994-11-26 WO PCT/EP1994/003921 patent/WO1995014481A1/en active IP Right Grant
- 1994-11-26 EP EP95901442A patent/EP0730463B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO1995014481A1 (en) | 1995-06-01 |
EP0730463A1 (en) | 1996-09-11 |
DE59409129D1 (en) | 2000-03-09 |
ATE189391T1 (en) | 2000-02-15 |
EP0730463B1 (en) | 2000-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0735870A4 (en) | Use of pla 2? inhibitors as treatment for alzheimer's disease | |
AU4621893A (en) | Compounds useful as hypoglycemic agents and for treating Alzheimer's disease | |
HUP9903906A3 (en) | Use of chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease | |
NZ237023A (en) | 17beta-substituted-4-aza-5alpha-androstan-3-ones and pharmaceutical compositions | |
WO1992011850A3 (en) | Use of calpain inhibitors in the inhibition and treatment of neurodegeneration | |
CA2289717A1 (en) | Novel therapy for constipation | |
WO1998020864A3 (en) | Use of selected non-steroidal antiinflammatory compounds for the prevention and the treatment of neurodegenerative diseases | |
UA41355C2 (en) | Agent for treating neuro-aids | |
AU7397094A (en) | Prevention and treatment of alzheimer's disease | |
ZA977310B (en) | Transdermal propentofylline compositions for the treatment of Alzheimer's disease. | |
IL106521A0 (en) | Pharmaceutical composition for the treatment or prevention of elevated intraocular pressure | |
MX9504023A (en) | Transdermally active pharmaceutical composition containing 5-aminolaevulinic acid. | |
HK1029937A1 (en) | Use of phanquinone for the treatment of alzheimer s disease. | |
AU5053296A (en) | Pharmaceutical agents for the treatment of Alzheimer's disease | |
IL105475A (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING 1a, 24(R) - DIHYDROXY-22(E)-DEHYDRO- VITAMIN D3 FOR TREATING OSTEOPOROSIS | |
AU7812794A (en) | Pharmaceutical compositions containing n-acetylcarnosine for the treatment of cataract | |
AU1067795A (en) | Use of lithium compounds in the treatment and prevention of alzheimer's disease | |
IL110780A0 (en) | Pharmaceutical compositions containing 1,3-bis(2-carboxy-chromon-5-yloxy)-propan-2-ol for the treatment of the common cold | |
ZA943342B (en) | The use of compositions for combating tumour diseases | |
AU2149797A (en) | Therapeutic agents for asthma | |
UA29461C2 (en) | An agent for treatment of amyloidosis, a method for treatment of amyloidosis | |
LT96094A (en) | The active ingredient of pharmaceutical composition for treating constipation | |
IL109235A0 (en) | Pharmaceutical compositions containing ureido derivatives for the treatment of lentivirus-induced diseases | |
IL105690A0 (en) | Pharmaceutical compositions for the treatment of arrhythmia | |
HU9600725D0 (en) | Transdermal device containing (e)-2-(p-fluorophenethyl)-3-fluoroallylamine for the treatment of alzheimer's disease |